---
document_datetime: 2023-09-21 20:59:22
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/novothirteen-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: novothirteen-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.4731153
conversion_datetime: 2025-12-14 13:55:11.940664
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## NovoThirteen

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0029/G            | This was an application for a group of variations. | 05/11/2021                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        |                                                                        |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------|
| PSUSA/10034 /202007 | Periodic Safety Update EU Single assessment - catridecacog                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/03/2021 | n/a        |                        | PRAC Recommendation - maintenance                                      |
| II/0026/G           | This was an application for a group of variations. Extension of indication to include long term prophylactic treatment of bleeding in patients with congenital factor XIII A-subunit deficiency, and as supplementary treatment to management of breakthrough bleeding episodes during regular prophylactic treatment regimen in patients with congenital factor XIII A-subunit deficiency as well as minor surgery based on the results of study NN1841- 3868 and the PRO-RBDD registry. As a consequence, sections 4.1, 4.2, 4.4, 4.6, 5.1, 5.2 of the SmPC and the RMP version 15 has been submitted. Annex IID and the package leaflet have been updated accordingly C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 23/07/2020 | 27/08/2020 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Novothirteen-H-C- 2284-II-26-G' |

<div style=\"page-break-after: always\"></div>

| IB/0027/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol   | 29/06/2020   | n/a        |                                  |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| PSUSA/10034 /201907 | Periodic Safety Update EU Single assessment - catridecacog                                                                                                                                                                                                                                                                                                             | 16/01/2020   | n/a        |                                  | PRAC Recommendation - maintenance |
| IA/0025             | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits                                                                                                                                                                                                              | 22/11/2019   | n/a        |                                  |                                   |
| PSUSA/10034 /201807 | Periodic Safety Update EU Single assessment - catridecacog                                                                                                                                                                                                                                                                                                             | 14/02/2019   | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0022             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                          | 08/08/2018   | n/a        |                                  |                                   |
| PSUSA/10034 /201707 | Periodic Safety Update EU Single assessment - catridecacog                                                                                                                                                                                                                                                                                                             | 08/03/2018   | n/a        |                                  | PRAC Recommendation - maintenance |
| R/0020              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                | 23/03/2017   | 24/05/2017 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0018   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 23/03/2017   | SmPC, Annex II, Labelling and PL   | The MAH updated the SmPC: - Section 4.4 to reflect that on-demand treatment was used in the extension study F13CD-3720: The on-demand treatment of acute bleeds or breakthrough bleeds with NovoThirteen was allowed per protocol in the late phase clinical development programme. One patient was treated on demand in a phase 3b extension study (F13CD-3720). Also, on-demand treatment is followed in a non-interventional post-authorisation safety study (NN1841-3868). Until further results are available, alternative treatment should be considered in such situations. - Section 5.1 to update the bleeding rate: In the F13CD-1725 extension trial F13CD-3720, the age- adjusted rate of bleeds that required treatment with a FXIII-containing product was estimated to be 0.021 bleeds per subject year with a 95% CI of [0.0062; 0.073] (model- based estimate corresponding to a mean age of the trial population of 31.0 years). The crude bleeding rate in the two trials, F13CD-1725 and F13CD-3720, not adjusted for age, were 0.138 and 0.043 respectively, corresponding to a total of 13 bleeds over 223 subject-years and a pooled rate of 0.058. - Section 5.2 to update the half-life: The half-life of NovoThirteen was assessed in the F13CD- 1725 trial from a limited blood sampling scheme at 1 hour, 14 and 28 days post dose. Based on FXIII activity measured by the Berichrom assay in patients with congenital FXIII deficiency, a geometric mean half-life of 11.8 days was estimated.   |
|-----------|---------------------------------------------------------------------------------------------------------------------|--------------|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PSUSA/10034 /201607   | Periodic Safety Update EU Single assessment - catridecacog                                                                                                                                                                                                                                                                                                           | 09/02/2017   | n/a        |                   | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-------------------------------------|
| IA/0019               | B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation                                                                                                                                                                                                                                                      | 28/11/2016   | n/a        |                   |                                     |
| IB/0017/G             | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                           | 11/11/2016   | n/a        |                   |                                     |
| II/0015               | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                       | 15/09/2016   | n/a        |                   |                                     |
| II/0013               | To update the SmPC section 4.8 Undesirable effects to reflect information that in a post-authorisation safety study transient non-neutralising antibodies were seen in a child with congenital FXIII deficiency after several years of treatment with NovoThirteen. In Annex II the MAH applied for a correction of an omission related to QRD template version 9.1. | 26/05/2016   | 24/05/2017 | SmPC and Annex II |                                     |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                         |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0014             | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                    | 22/04/2016 | n/a |                                   |
| II/0012/G           | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 01/04/2016 | n/a |                                   |
| PSUSA/10034 /201507 | Periodic Safety Update EU Single assessment - catridecacog                                                                                                                                                                                                                                                                                                                                                                                                | 11/02/2016 | n/a | PRAC Recommendation - maintenance |
| IB/0009             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                          | 01/10/2015 | n/a |                                   |
| IB/0010             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                             | 10/08/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0007             | To extend the shelf life of the primary and secondary reference materials of the active substance from 5 to 10 years. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data       | 16/02/2015   | n/a        |                       |                                                                                 |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|---------------------------------------------------------------------------------|
| PSUSA/10034 /201407 | Periodic Safety Update EU Single assessment - catridecacog                                                                                                                                                                                                                                         | 12/02/2015   | n/a        |                       | PRAC Recommendation - maintenance                                               |
| IB/0005/G           | This was an application for a group of variations. B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                    | 17/10/2014   | n/a        |                       |                                                                                 |
| PSUV/0004           | Periodic Safety Update                                                                                                                                                                                                                                                                             | 11/09/2014   | n/a        |                       | PRAC Recommendation - maintenance                                               |
| PSUV/0003           | Periodic Safety Update                                                                                                                                                                                                                                                                             | 06/03/2014   | n/a        |                       | PRAC Recommendation - maintenance                                               |
| II/0002             | Extension of indication to include the treatment of bleeding in children with congenital factor XIII A- subunit deficiency below 6 years of age. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated regarding posology recommendations, as well as safety, efficacy and | 23/01/2014   | 21/02/2014 | SmPC, Annex II and PL | Please refer to the Scientific Discussion NovoThirteen EMEA/H/C/002284/II/0002. |

<div style=\"page-break-after: always\"></div>

|         | pharmacokinetics information in this patient population. In addition, section 6.6 of the SmPC is updated in order to add a recommendation for the dilution of the reconstituted product for patients less than 24 kg. The Package Leaflet is updated in accordance. Furthermore, the PI is being brought in line with the latest QRD template version 9.0. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0280 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                              | 17/04/2013 | n/a |